News

Dynavax Technologies (NASDAQ:DVAX), a biotechnology company focused on vaccines, released its results for the second quarter of 2025 on August 7, 2025. The company posted GAAP revenue of $95.4

Cidara Therapeutics (NASDAQ:CDTX), a biotechnology company focused on the development of innovative therapies for infectious diseases and oncology, released its second-quarter 2025 earnings on

Cytokinetics (NASDAQ:CYTK), a late-stage biopharmaceutical company focused on cardiovascular disease, reported earnings for Q2 FY2025 on August 7, 2025. The headline news was a dramatic

Corvus Pharmaceuticals (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies, released its earnings results for Q2 2025 on August 7, 2025

scPharmaceuticals (NASDAQ:SCPH), a commercial-stage pharmaceutical company focused on subcutaneous drug delivery for heart failure and chronic kidney disease patients, delivered its second quarter

Intellia Therapeutics (NASDAQ:NTLA), a biotechnology company developing CRISPR-based gene-editing therapies, reported second quarter 2025 results on August 7, 2025. The headline news was a

Dentsply Sirona (NASDAQ:XRAY), a major player in dental products and technologies, released its second quarter results on August 7, 2025. The company reported GAAP revenue of $936 million and

Avadel Pharmaceuticals Plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to improve lives, released its earnings for Q2 2025 on August 7, 2025. The headline news is

Akebia Therapeutics (NASDAQ:AKBA), a biopharmaceutical company specializing in kidney disease treatments, reported its earnings on August 7, 2025, covering results for the quarter. The headline news

Insulet (NASDAQ:PODD), a medical device company specializing in wearable insulin delivery systems, released its second quarter 2025 earnings on August 7, 2025. The headline news was strong

Immunic (NASDAQ:IMUX), a late-stage biotechnology company focused on autoimmune and inflammatory diseases, released its second quarter 2025 results on August 7, 2025. The quarter was marked by

Ecovyst (NYSE:ECVT), a specialty catalyst and chemicals provider focused on industrial and environmental markets, released its second-quarter 2025 results on August 7, 2025. The main headlines: the

Incoming patent cliffs regarding some of Pfizer's (NYSE: PFE) largest revenue streams have been pressuring the pharmaceutical stock. The price is down, but its dividend payout keeps rising. Last

Veracyte (NASDAQ:VCYT), a leader in advanced cancer diagnostics, reported results for Q2 2025 on August 6, 2025. The headline news: the company outperformed expectations on both revenue and

CareDx (NASDAQ:CDNA), a molecular diagnostics company specializing in transplant care solutions, released its results for the second quarter of fiscal 2025 on August 6, 2025. The big news from the

Innoviva (NASDAQ:INVA), a pharmaceutical company specializing in royalties and specialty therapeutics, reported second-quarter earnings on August 6, 2025. The company announced earnings per share

Orion (NYSE:OEC), a leading global producer of carbon black, reported its second quarter results on August 6, 2025. The most notable news was that GAAP revenue came in at $466.4 million for Q2 2025

Pulmatrix (NASDAQ:PULM), a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that

Seres Therapeutics (NASDAQ:MCRB), a clinical-stage biotech focused on microbiome therapeutics, released its second quarter 2025 earnings on August 6, 2025. The main highlight was a narrowing net

AnaptysBio (NASDAQ:ANAB), a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, released its Q2 2025 earnings on August 6

Royalty Pharma Plc (NASDAQ:RPRX), a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts—its

BeOne Medicines (NASDAQ:ONC), a global oncology-focused pharmaceutical company, released results for Q2 2025 on August 6, 2025. The most notable news was a sustained acceleration across revenue

UnitedHealth Group (NYSE: UNH) has been in the news over the past several months, but not positively. Unfortunately, the CEO of its healthcare unit, Brian Thompson, was shot and killed late last